Replies to post #140882 on Biotech Values

[DewDiligence]

CHMP approves Afinitor in advanced breast cancer:

http://www.novartis.com/newsroom/media-releases/en/2012/1621353.shtml

…the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Afinitor (everolimus) tablets, in combination with exemestane, for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.

Afinitor has so many approved indications, I’ve lost track of the count. I think it’s safe to say that Afinitor has exceeded the commercial expectations of almost everyone inside and outside of NVS.